ArticleAnnals of clinical microbiology and antimicrobials2025
Magnitude of poor multidrug-resistant tuberculosis treatment outcome among multidrug-resistant tuberculous patients at tertiary hospital, South West Ethiopia.
Article in Annals of clinical microbiology and antimicrobials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe persistent spread of multiple drug-resistant tuberculosis (MDR-TB) is one of the most pressing and challenging issues facing the global TB control efforts. Standard first-line treatment for MDR TB is nearly ineffective for patients infected with strains of the disease that are resistant to isoniazid and rifampicin.
objectiveTo assess the magnitude of poor MDR-TB treatment outcomes among MDR-TB patients at the MDR-TB clinic, tertiary Hospital, Southwest, Ethiopia.
methodsA retrospective cross-sectional study was conducted at the MDR-TB clinic, Mattu Karl Comprehensive Specialized Hospital (MKCSH), from 2018 to 2024. A data collection checklist was used to collect information on sociodemographic, clinical characteristics, medication, and treatment outcomes from the patient's medical cards. The collected data were cleaned, coded, entered, and analyzed using SPSS version 20 computer software. Descriptive data analysis was done to describe variables by percent and frequency. Data were presented in tables and pie charts.
resultA total of 72 (54.2% male and 47.8% female) MDR-TB patients were included in this study analysis. Among a total, 54.2% were men. The mean age of the patients was 31.42 years with a standard deviation of 7.81 years, and 25% were positive for human immunodeficiency virus (HIV). The most common adverse drug reaction was gastric disturbance (45.8%). The majority, 79.2% had a successful outcome: 75% were cured and 4.2% have completed treatment. The magnitude of poor MDR-TB treatment outcome was 20.8%: 12.5% were death and 8.3% defaulted from treatment.
conclusionThe magnitude of poor MDR-TB treatment outcomes among MDR-TB patients was high. Strengthening patient support systems and optimizing treatment protocols are essential strategies to reduce the prevalence of poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.